NDC 72769-181
Rapivab
Peramivir
Rapivab is a Intravenous Solution in the Human Prescription Drug category. It is labeled and distributed by Biocryst Pharmaceuticals, Inc.. The primary component is Peramivir.
| Product ID | 72769-181_4fd5d946-6027-4662-b66b-9ccd68f446b7 |
| NDC | 72769-181 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Rapivab |
| Generic Name | Peramivir |
| Dosage Form | Solution |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2014-12-20 |
| Marketing Category | NDA / NDA |
| Application Number | NDA206426 |
| Labeler Name | BioCryst Pharmaceuticals, Inc. |
| Substance Name | PERAMIVIR |
| Active Ingredient Strength | 600 mg/60mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
Packaging
NDC 72769-181-03
3 VIAL, GLASS in 1 CARTON (72769-181-03) > 20 mL in 1 VIAL, GLASS (72769-181-01)
| Marketing Start Date | 2014-12-20 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Drug Details
NDC Crossover Matching brand name "Rapivab" or generic name "Peramivir"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 61364-181 | Rapivab | peramivir |
| 72769-181 | Rapivab | peramivir |
Trademark Results [Rapivab]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 RAPIVAB 86141883 4778059 Live/Registered |
SEQIRUS UK LIMITED 2013-12-12 |
 RAPIVAB 85105828 not registered Dead/Abandoned |
BioCryst Pharmaceuticals, Inc. 2010-08-12 |
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.